Fig. 5From: Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironmentSI-2 treatment alters the tumor-infiltrating immune cell repertoire in 4T1 breast tumors. A–D Quantification of CD4 + T cells (A), CD8 + T cells (B), CD56 + NK cells (C) and Ifng (D) in 4T1 breast tumors in BALB/c mice treated with SI-2 (2.5 mg/kg) or vehicle, as determined by IHC with an antibody against their respective target protein. The quantification of the percentage of labeled cells (PLC) with CD4, CD8, CD56, and Ifng in 4T1 breast tumors is shown in the graphBack to article page